Treatment of kaposi sarcoma in human immunodeficiency virus-1-infected mozambican children with antiretroviral drugs and chemotherapy

Pediatric Infectious Disease Journal

Volumn 30, Issue 10, 2011, Pages 891-893

  Vaz, Paula ^a   MacAssa, Eugenia ^a   Jani, Ilesh ^b   Thome, Beatriz ^a   Mahagaja, Epifanio ^b   Madede, Tavares ^a   Muando, Valeria ^a   Biberfeld, Gunnel ^c   Anderson, Soren ^c   Blanche, Stephane ^d  

^a MAPUTO CENTRAL HOSPITAL   (Mozambique)

^b INSTITUTO NACIONAL DE SAÚDE   (Mozambique)

^c KAROLINSKA INSTITUTE   (Sweden)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

AIDS; children; HIV; Kaposi Sarcoma; paclitaxel

Indexed keywords

ANTIRETROVIRUS AGENT; PACLITAXEL; PREDNISONE;

ADOLESCENT; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; DRUG TOLERABILITY; FATIGUE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; KAPOSI SARCOMA; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUTROPENIA; PRESCHOOL CHILD; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; SCHOOL CHILD; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 80052920846     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318228fb04     Document Type: Article

References (12)

1. Serraino D, Franceschi S. Kaposi's sarcoma and non-Hodgkin's lympho-mas in children and adolescents with AIDS. AIDS. 1996;10:643-647. (Pubitemid 26162993)
2. Manji KP, Amir H, Maduhu IZ. Aggressive Kaposi's sarcoma in a 6-month-old African infant: case report and review of the literature. Trop Med Int Health. 2000;5:85-87. (Pubitemid 30159124)
3. Gantt S, Kakuru A, Wald A, et al. Clinical presentation and outcome of epidemic Kaposi sarcoma in Ugandan children. Pediatr Blood Cancer. 2010;54:670-674.
4. Dupin N, Rubin De Cervens V, Gorin I, et al. The influence of highly active antiretroviral therapy on AIDS-associated Kaposi's sarcoma. Br J Derma-tol. 1999;140:875-881. (Pubitemid 29238459)
5. Lebbé C, Blum L, Pellet C, et al. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma. AIDS. 1998;12:F45-F49. (Pubitemid 28190688)
6. Bower M, Weir J, Francis N, et al. The effect of HAART in 254 consecutive patients with AIDS-related Kaposi's sarcoma. AIDS. 2009;23:1701-1706.
7. Krown SE, Metroka C, Wernz JC. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol. 1989;7:1201-1207. (Pubitemid 19220121)
8. Updated WHO recommendations. Available at: http://www.who.int/hiv/pub/ paediatric/infants2010/en/index.html. Accessed April 4, 2011.
9. Bihl F, Mosam A, Henry LN, et al. Kaposi's sarcoma-associated herpes-virus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma. AIDS. 2007;21:1245-1252. (Pubitemid 46883478)
10. Feller L, Lemmer J. Insights into pathogenic events of HIV-associated Kaposi sarcoma and immune reconstitution syndrome-related Kaposi sarcoma. Infect Agent Cancer. 2008;21:1.
11. Dhillon T, Stebbing J, Bower M. Paclitaxel for AIDS-associated Kaposi's sarcoma. Expert Rev Anticancer Ther. 2005;5:215-219. (Pubitemid 40553088)
12. André N, Meille C. Taxanes in paediatric oncology: and now? Cancer Treat Rev. 2006;32:65-73.